Lucerne Biosciences
Wilmington
Delaware
United States
8 articles about Lucerne Biosciences
-
Lucerne Biosciences Engages Matsuman709@yahoo.com As "Third-Party Intermediary" To Handle Sensitive Information From The Public Regarding "The Patent '813 Story"
3/11/2016
-
Lucerne Biosciences Takes Business To New Haven, Connecticut, Bolstered By APS Holding Global Marketing Agreement Of "The Patent '813 Story
3/3/2016
-
Dramatic Turn In Story Of Invalidated '813 Patent For Treating Binge Eating Disorder As Owner Lucerne Biosciences Provides Patent Board Profile Of Itself And Its High 40-75% Misrepresentation Rate
1/21/2016
-
Lucerne Biosciences Completes Sourcing Investigation Into Shire's IPR That Led To The Invalidation Of The '813 Patent
1/15/2016
-
Lucerne Biosciences Completes Sourcing Investigation Into Shire's IPR That Led To The Invalidation Of The '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase Of Its Counter-Intelligence Technology
1/12/2016
-
PTAB Invalidates Lucerne Biosciences' '813 Patent For The Treatment Of Binge Eating Disorder With Lisdexamfetamine Dimesylate
6/15/2015
-
LCS Group Announces Exclusive License From Lucerne Biosciences To Commercialize '813 Patent And '249 Application Through Shire's Marketing Of Lisdexamfetamine Dimesylate For Binge Eating Disorder
5/14/2015
-
Lucerne Biosciences Announces Publication Of Claimed Methods For Treating Binge Eating Disorder With Lisdexamfetamine Dimesylate
3/6/2015